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Type 1 pili have long been considered the major virulence factor enabling colonization of the
urinary bladder by uropathogenic Escherichia coli (UPEC). The molecular pathogenesis of
pyelonephritis is less well characterized, due to previous limitations in preclinical modeling
of kidney infection. Here, we demonstrate in a recently developed mouse model that beyond
bladder infection, type 1 pili also are critical for establishment of ascending pyelonephritis.
Bacterial mutants lacking the type 1 pilus adhesin (FimH) were unable to establish kidney
infection in male C3H/HeN mice. We developed an in vitro model of FimH-dependent UPEC
binding to renal collecting duct cells, and performed a CRISPR screen in these cells, identi-
fying desmoglein-2 as a primary renal epithelial receptor for FimH. The mannosylated extra-
cellular domain of human DSG2 bound directly to the lectin domain of FimH in vitro, and
introduction of a mutation in the FimH mannose-binding pocket abolished binding to DSG2.
In infected C3H/HeN mice, type 1-piliated UPEC and Dsg2 were co-localized within collect-
ing ducts, and administration of mannoside FIM1033, a potent small-molecule inhibitor of
FimH, significantly attenuated bacterial loads in pyelonephritis. Our results broaden the bio-
logical importance of FimH, specify the first renal FimH receptor, and indicate that FimH-tar-
geted therapeutics will also have application in pyelonephritis.
Author summary
Urinary tract infections (UTIs) are among the most common bacterial infections in
humans. While much has been discovered about how E. coli cause bladder infections, less
is known about the host-pathogen interactions that underlie kidney infection
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(pyelonephritis). We employed recently developed mouse models to show that bacterial
surface fibers called type 1 pili, which bear the adhesive protein FimH and are known to
mediate E. coli binding to bladder epithelium, are also required for ascending kidney
infection. We developed a cell-culture model of bacterial binding to renal collecting duct,
then performed a screen using the gene-editing tool CRISPR to identify the first known
FimH receptor in the kidney. This epithelial cell-surface protein, desmoglein-2, was
shown to directly bind FimH, and we localized this binding to specific extracellular
domains of DSG2. Further, we showed that mannosides, small-molecule FimH inhibitors
currently in development to treat bladder infection, are also effective in experimental kid-
ney infection. Our study reveals a novel host-pathogen interaction during pyelonephritis
and demonstrates how this interaction may be therapeutically targeted.
Introduction
Bacterial adhesion to urinary tract epithelium is a critical step in establishing urinary tract
infection (UTI). Strains of uropathogenic Escherichia coli (UPEC), the main causative agents
of UTIs, carry in their genomes a variable repertoire of adhesive pili assembled via the canoni-
cal chaperone-usher pathway (CUP) [1,2]. Given their importance in host-pathogen interac-
tions, UPEC adhesins including CUP pili have received considerable attention as mediators of
pathogenesis and potential therapeutic targets [2–5]. Within the mammalian bladder, UPEC
employ type 1 pili terminating in the FimH adhesin, which binds α-D-mannose with stereo-
chemical specificity. FimH-mediated UPEC binding to mannosylated uroplakins that coat the
luminal surfaces of superficial uroepithelial (facet) cells is a key event in the pathogenesis of
cystitis [6–11]. UPEC can subsequently be internalized into facet cells, where they replicate
and establish intracellular bacterial communities (IBCs) [12–16]. Bacteria within IBCs are pro-
tected from phagocytosis and other host defenses, and this community behavior within the
bladder is a critical component of UPEC cystitis [17,18].
Less is known about the host-pathogen interactions enabling establishment of upper-tract
UTIs, including pyelonephritis and renal abscess. Another CUP pilus, the P pilus, is tipped
with the PapG adhesin, which has been implicated in human pyelonephritis [2,19–21]. How-
ever, data regarding the participation of P pili in murine pyelonephritis vary among prior stud-
ies, potentially due to disparities in host and bacterial strains used, and species specificity in
the glycolipid receptors for PapG [21,22]. Preclinical modeling of UTIs has been performed
predominantly in female mice, and in a majority of murine backgrounds, upper-tract UTI
resolves spontaneously and without significant sequelae [23,24]. Historically, female mice have
been utilized in models of experimental UTI, typically initiated by catheter-directed inocula-
tion of the mouse bladder; reliable catheter access to the male mouse bladder is technically
challenging [25–28]. We previously developed an inoculation technique for initiating UTI in
both male and female mice; when normal anatomic protections in males were thus bypassed,
males evidenced more severe UTI, reflected throughout the course of infection by higher blad-
der and kidney bacterial loads, leukocyte infiltration, and inflammation [29]. Of note, these
findings aligned with human epidemiologic data showing higher morbidity from complicated
UTI in men, and higher UTI incidence in women with polycystic ovary syndrome (a common
hyperandrogenic state) [30–36]. In C3H/HeN mice (a background inherently featuring vesi-
coureteral reflux, a primary risk factor for upper-tract UTI in humans), males and androgen-
exposed females developed severe pyelonephritis and renal abscesses [29,37]. Renal infection
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was nucleated by collections of UPEC occupying collecting ducts and more proximal segments
of the nephron, which we termed kidney bacterial communities (KBCs) [37].
The consistent development of severe pyelonephritis in this model enables detailed
investigation of bacterial and host factors involved in the establishment of ascending
upper-tract UTI. We identified a previously unappreciated role in the kidney for the man-
nose-binding type 1 pilus adhesin FimH, previously recognized as a major urovirulence
factor within the bladder. High-affinity mannosides, which neutralize FimH function and
are in development for the treatment of cystitis [4,5,38,39], here significantly lowered bac-
terial burdens in the kidneys of mice with established pyelonephritis. To specify host fac-
tors required for upper-tract UTI, we performed a CRISPR-Cas9 screen in immortalized
murine renal epithelial cells and identified desmoglein-2 (Dsg2) as a candidate receptor for
FimH. The lectin domain of FimH (but not FimH with a point mutation that abolishes
mannose binding) directly bound to the extracellular domain of human desmoglein-2
(DSG2). Finally, we observed co-localization of UPEC with Dsg2 in the collecting ducts of
mice with ascending pyelonephritis. Our studies demonstrate that disruption of FimH
binding to renal tubular epithelium represents a potential therapeutic intervention during
pyelonephritis.
Results
Type 1 pili are required for both bladder and kidney infection in male
C3H/HeN mice
Type 1 pili have long been implicated in pathogenesis of UPEC cystitis, but only recently have
new experimental models enabled molecular interrogation of their role in pyelonephritis. We
infected male C3H/HeN mice with either wild-type UTI89 (a prototypic UPEC strain), or
UTI89ΔfimH, an isogenic mutant lacking the type 1 pilus adhesin [16,40]. Two weeks post
infection (wpi), UTI89ΔfimH was sharply attenuated compared to wild-type in bladder and
kidney bacterial loads (p<0.0001; Fig 1A) and in incidence of visible renal abscess (1/16 vs 13/
13; p<0.0001). We confirmed that UTI89ΔfimH reached the kidney normally following blad-
der inoculation, as kidney bacterial loads 24 hours post infection (hpi) were equivalent to
wild-type (S1 Fig). Of note, an analogous defect was confirmed using the urosepsis UPEC iso-
late CFT073, whose isogenic CFT073ΔfimH mutant failed to colonize the kidney 2 wpi (S2
Fig). Using immunofluorescence microscopy, we demonstrated type 1 pili expression by
UPEC in KBCs located within renal abscesses 2 wpi (Fig 1B). As UTI89 carries ten full or par-
tial CUP operons [41], we similarly tested deletion mutants in each of the annotated CUP pili.
No other CUP pilus mutants exhibited a defect in bladder or kidney infection in male C3H
mice 2 wpi, after inoculation either alone (S3 Fig) or in competition with antibiotic-tagged
UTI89 (S4 Fig).
The pilin and lectin domains of FimH together exist in an equilibrium between tense and
relaxed states with differential mannose binding affinity. Conversion between these states is
governed in part by a catch-bond mechanism [9,42–44]. In the relaxed state, the FimH lectin
domain samples conformational ensembles, allowing it to act as a molecular tether, with the
mannose binding pocket in a conformation able to bind mannose tightly; in the tense state,
the pocket is open and thus binds mannose only weakly [8]. In the bladder, the ability of FimH
to transition between these states enables optimal epithelial binding by UPEC [8,45,46]. We
infected male C3H/HeN mice with wild-type UTI89 or with UTI89ΔfimH complemented with
FimHA27V/V163A, a variant that predominantly adopts the relaxed conformation (high-affinity
mannose-binding state). Paradoxically, UPEC expressing this variant are attenuated during
cystitis in female mice [8,45,46]. Here, we found similarly that UTI89 FimHA27V/V163A also
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failed to establish pyelonephritis, with significantly lower bacterial loads in kidneys (p = 0.001)
as well as bladder (p<0.0001) compared to wild-type UTI89 (S5 Fig). Further, the type 1 pilus
rod, formed from FimA subunits, normally can unwind from a tightly coiled helix to a more
linearized rod; this action is hypothesized to help UPEC withstand the shear force of urine
flow [47–49]. A variant in the type 1 pilus helical rod, FimAA22R, requires less force to adopt
the unwound form, but UPEC expressing this variant are attenuated in the female mouse blad-
der [50]. We found that UTI89 expressing FimAA22R was also attenuated in the kidneys
(p = 0.0038) and bladders (p<0.0001) of male C3H/HeN mice 2 wpi (S5 Fig). Thus, the con-
formational dynamics of type 1 pili, critical in establishing bladder infection, are similarly
important in ascending pyelonephritis. Collectively, our data demonstrate that beyond their
well-described role in establishing bladder infection, UPEC type 1 pili are also important in
initiating ascending pyelonephritis and renal abscess.
Fig 1. Type 1 pili are required for bladder and kidney infection. A) Male C3H/HeN mice were infected with UTI89
(closed circles) or UTI89ΔfimH (open diamonds), and organs were harvested 2 wpi. Bacterial loads after WT infection
were significantly higher than with ΔfimH in both the bladder and kidneys (����p<0.0001). Horizontal bars indicate
geometric mean, and dotted line indicates limit of detection. n = 13–16 mice per group over 3 independent
experiments. B) Immunofluorescence microscopy of C3H/HeN male kidney 2 wpi with UTI89, showing expression of
type 1 pili within kidney bacterial communities (magnified in inset; green, anti-type 1 pili; red, SYTO 61 nuclear stain).
Scale bar, 20 μm.
https://doi.org/10.1371/journal.ppat.1009314.g001
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Murine collecting duct cells display type 1 pili-dependent UPEC binding
The collecting duct is the first nephron segment encountered by ascending UPEC. Consistent
with prior findings [51,52], ascending UPEC were located within collecting ducts in C3H/
HeN mice 5 dpi (Fig 2A). Therefore, we chose mouse intramedullary collecting duct (IMCD-
3) cells to establish an in vitro model of type 1 pili binding to kidney epithelium. In standard
bacterial binding assays, UTI89 ΔfimH was significantly attenuated compared to wild-type
UTI89 (Fig 2B), recapitulating what we observed in in vivo infection. Following IMCD-3 cell
infection and anti-E. coli antibody staining, we confirmed by flow cytometry the in vitro bind-
ing defect of ΔfimH (Fig 2C and 2D). This defect was complemented by chromosomal re-inte-
gration of wild-type fimH, but not by integration of the fimHQ133K mutant, which lacks
mannose binding activity [10] (S6 Fig). The binding defect was also replicated in CFT073
ΔfimH (S6 Fig). Finally, UPEC binding to collecting duct cells was significantly inhibited by
methyl α-D-mannopyranoside and to an even greater extent by mannoside FIM1033 (S7 Fig).
Thus, the in vivo requirement for type 1 pilus function is reflected in in vitro binding of UPEC
to IMCD-3 cells.
Fig 2. Murine collecting duct cells display type 1 pili-dependent UPEC binding. A) Early intratubular colonies of
UPEC (green) were localized 5 dpi in male C3H/HeN mice collecting duct tubules (AQP2+, red; DAPI, blue; scale bar,
10 μm). B) To intramedullary collecting duct (IMCD-3) cells, WT UTI89 (filled circles) displayed significantly higher
levels of bacterial binding than ΔfimH (open diamonds; ����p<0.0001) (MOI 20). Horizontal bars indicate geometric
mean. n = 12 samples per group over 4 independent experiments. C, D) Binding of IMCD-3 cells by UTI89 or ΔfimH
was quantified by flow cytometry after gating on single cells. C) FITC signal (anti-E. coli) was evident in IMCD-3 cells
infected with wild-type UTI89 (navy blue) compared with medium alone (green); infection with ΔfimH yielded
negligible signal (orange). D) Cells infected with UTI89 displayed significantly higher median fluorescence intensity
(MFI) than those treated with medium alone or ΔfimH (����p<0.0001). n = 8–15 samples per group over 6
independent experiments.
https://doi.org/10.1371/journal.ppat.1009314.g002
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A CRISPR screen identifies candidate type 1 pilus receptor desmoglein-2
Although type 1 pili are well known as critical virulence factors in the bladder [6–11], they
have not been implicated in ascending pyelonephritis, and a cognate receptor has not been
identified. To screen for host genes participating in type 1 pili-dependent binding of UPEC to
collecting duct epithelium, we performed a genome-wide CRISPR-Cas9 screen using the Brie
sgRNA library in IMCD-3 cells (Fig 3A), providing 4× nominal coverage of each gene within
the mouse genome [53]. The pooled library of edited cells were inoculated with UPEC, fixed
and stained, and subsequently flow-sorted for the population of cells with the lowest fluores-
cence (Fig 3A). Genomic DNA was extracted from sorted cells, subjected to Illumina sequenc-
ing, and analyzed using the probability mass function of a hypergeometric distribution to
identify candidate genes statistically associated with bacterial binding (S1 Table) [53,54].
Among these candidates (Fig 3B), we focused on genes encoding proteins that would localize
to the cell surface and could be available to interact with bacterial pili [55–57]. The screen
revealed deficient UPEC binding to cells edited with guides targeting desmoglein-2 (Dsg2; Fig
3B), which encodes a mannosylated cell junctional protein displayed on kidney tubular epithe-
lia throughout the nephron [55,57–59]. By immunofluorescence microscopy of IMCD-3 cells
incubated with UPEC, we observed co-localization of UPEC with Dsg2 (Fig 3C).
FimH binds DSG2 in vitro
Desmoglein-2 is a member of the cadherin superfamily and in humans and mice comprises
five extracellular cadherin (EC) domains, a single transmembrane segment, and an intracel-
lular domain (Fig 4A). To determine whether desmoglein-2 binds directly to FimH, we
Fig 3. A lentiviral CRISPR screen identifies candidate type 1 pilus receptor desmoglein-2. A) Schematic of screen design. To
screen for host genes responsible for type 1 pili-dependent binding to this cell line, we transduced the Brie library of mouse guide
RNAs into IMCD-3 cells bearing Cas9, providing 4× nominal coverage of each gene within the mouse genome. Cells were then
bound (MOI 150) by UTI89 and sorted by fluorescent labeling, isolating cells unbound by bacteria. Genomic DNA was extracted
and sequenced, identifying candidate genes that may be required for UPEC binding to IMCD-3 cells. B) Volcano plot results from
sorted and sequenced cells. Colored dots represent genes having an average log2 fold change>0.5 and a–log10(p-value)>2.5. C)
After in vitro binding, desmoglein-2 (red) on IMCD-3 cells co-localized with UPEC (green); scale bar, 5 μm. Lower panel
demonstrates co-localization in orthogonal view of z-stack projection.
https://doi.org/10.1371/journal.ppat.1009314.g003
PLOS PATHOGENS Type 1 pili in UPEC pyelonephritis
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1009314 January 29, 2021 6 / 23
generated two forms of recombinant 6×His-tagged human DSG2 (EC1-5, amino acids
A1-A553) [58]: in wild-type Expi293F cells, and from Expi293F GnTI- cells (which lack
complex N-glycans and instead exhibit uniform GlcNAc2Man5 glycosylation). We also
purified the lectin domain of FimH (FimHLD, amino acids F1-G160) from E. coli (S8 Fig).
By biolayer interferometry (BLI), FimHLD bound to DSG2 EC1-5 from wild-type cells with
an apparent binding affinity of 1.6 μM (Fig 4B and S9 Fig). In comparison, DSG2 EC1-5
purified from GnTI- cells exhibited higher binding to FimHLD (KD,apparent = 484 nM,
p = 0.008; Fig 4B), consistent with preferential binding of FimHLD to highly mannosylated
structures. In contrast, purified FimHQ133K did not bind to either variant of DSG2 EC1-5
(p = 0.036; Fig 4B). Finally, FimHLD bound only minimally to DSG2 EC1-3 (amino acids
A1-N332; p = 0.015 vs EC1-5; Fig 4B). Taken together, these data show that FimH binds the
extracellular portion of DSG2 in a mannose-dependent manner, and that DSG2 domains
EC4 and/or EC5 mediate FimH binding.
To validate Dsg2 as a UPEC receptor, we edited IMCD-3 cells with CRISPR-Cas9 to achieve
specific deletion of Dsg2. Though hundreds of edited clones were screened, no clones entirely
lacking Dsg2 expression were obtained, suggesting that complete Dsg2 deletion is
Fig 4. The FimH lectin domain directly binds DSG2 EC1-5 in a mannose-specific manner. A) Schematic of human
DSG2, with five extracellular cadherin domains (EC1-5; blue) followed by a single transmembrane (TM) segment and
the cytoplasmic (desmoglein) portion of the protein (gray). O-linked mannoses are represented by green dots, N-
linked glycosylation sites with terminal mannose shown by yellow dots. B) Normalized BLI signal (mean ± SD) of
DSG2 ectodomains (immobilized at 1 μg/mL) binding to FimHLD or FimHQ133K (10 μM). Relative BLI signals were
normalized to amount of captured WT DSG2 EC1-5. DSG2 EC1-5 and DSG2 EC1-3 were purified from wild-type
Expi293F cells, and DSG2 EC1-5 was also purified from Expi293F GnTI- cells (which lack complex N-glycans and
instead exhibit uniform GlcNAc2Man5 glycosylation). �p = 0.036 (EC1-5 WT vs Q133K), ��p = 0.008 (EC1-5 WT vs
GnTI-), �p = 0.015 (EC1-5 vs EC1-3). n = 3–5 independent experiments per group.
https://doi.org/10.1371/journal.ppat.1009314.g004
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physiologically detrimental. Of note, germline Dsg2 deletion in mice is lethal [60]. We did
identify two gene-edited clones (namely C4 and F11) that exhibited sharply reduced Dsg2 tran-
script expression (Fig 5A); by quantitative immunoblot of cell lysates, these knock-down
clones expressed significantly less Dsg2 protein than wild-type IMCD-3 cells (Fig 5B; median
C4/WT ratio 4.3%, p = 0.0022; median F11/WT ratio 4.7%, p = 0.0087). By flow cytometry,
median binding of C4 and F11 cells by UPEC was decreased by 33% and 46% compared with
WT IMCD-3 cells (p = 0.0235 and 0.0032, respectively; Fig 5C and 5D).
Targeting the Dsg2-FimH interaction during in vivo infection
In the kidneys of UPEC-infected C3H/HeN mice, we identified UPEC within Dsg2+, aqua-
porin-2+ collecting ducts 5 dpi (Fig 6A and 6B). Across multiple sections from several infected
mice, of 239 intratubular UPEC colonies visualized 5 dpi, 228 (95%) resided in Dsg2+ tubules.
Finally, we hypothesized that if the Dsg2-FimH interaction was important for pyelonephri-
tis, mannosides could be employed therapeutically in our mouse model. Male C3H/HeN mice
were inoculated with UTI89, and early KBCs were allowed to form over 5 days [37,61]; mice
Fig 5. Dsg2 knock-down cells exhibit a UPEC binding defect. A) qPCR of desmoglein-2 normalized to GAPDH in
IMCD-3 Dsg2 knock-down clones C4 and F11 (C4/WT �p = 0.0458, F11/WT �p = 0.0449). n = 3 independent samples
per group, error bars represent standard error of the mean. B) Quantitative immunoblot for Dsg2 in clones C4 and F11,
normalized to β-actin (median C4/WT ratio 4.3%, � p = 0.0022; median F11/WT ratio 4.7%, ��p = 0.0087). Inset shows
representative blot. n = 6 independent samples per group. C, D) Binding of UTI89 to IMCD-3 cells or to clones C4 and
F11 (MOI 150) was quantified by flow cytometry after gating on single cells. C) Histogram of FITC shift (anti-E. coli) in
infected IMCD-3 cells. Medium alone (green) or infection with ΔfimH reflects no shift (orange); clones C4 and F11
(light and dark pink respectively) exhibited significantly decreased UPEC binding compared to WT IMCD-3 cells (navy
blue). D) Wild-type IMCD-3 cells infected with UTI89 displayed significantly higher median fluorescence intensity
(MFI) than clones C4 and F11 (C4/WT �p = 0.0235; F11/WT ��p = 0.0032). n = 15 samples per group over 5
independent experiments.
https://doi.org/10.1371/journal.ppat.1009314.g005
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were then treated with mannoside FIM1033 (formerly termed 29R [5]) (Fig 6A). Compared
with mock-treated mice, bladder and kidney bacterial loads were significantly reduced by
mannoside treatment for 24 h (kidney p = 0.0434, bladder p = 0.0255; Fig 6C) and even more
so with treatment for 48 h (kidney p = 0.0042, bladder p = 0.0003; Fig 6D). These in vivo data
support a model in which desmoglein-2 on collecting duct epithelium serves as a receptor for
UPEC FimH during pyelonephritis in vivo.
Discussion
In this study, we detail the importance of type 1 pili in host-pathogen interaction during ascend-
ing pyelonephritis and identify desmoglein-2 as the first receptor for FimH on renal tubular epi-
thelium. Our findings in male C3H mice confirm that type 1 pili are essential for cystitis (as in
female mice [6–11]), but more importantly provide both in vitro and in vivo evidence of the func-
tion of FimH in bacterial infection of the kidney. Furthermore, our ability to mitigate kidney
infection with mannosides suggests that type 1 pilus-directed therapeutics currently under devel-
opment for recurrent cystitis [2,4,5,38,39] may also be useful in pyelonephritis.
Compared to bacterial cystitis, significantly less is known about the pathogenesis of UPEC
pyelonephritis, primarily due to the fact that female mice of most backgrounds resolve kidney
infection spontaneously [23,24]. Work in humans has identified genetic factors that confer
susceptibility to pyelonephritis and renal scarring, including polymorphisms reducing IRF3 or
CXCR1 (encoding IL-8 receptor) expression, in certain UTI-prone kindreds [62–65]. P pili
have been considered the major adhesin in kidney infection [2,19,21]. This work has been
complicated by allelic variation in the P pilus adhesin PapG (UTI89 encodes the PapGIII allelic
variant but does not express P pili under laboratory conditions, while the common
Fig 6. Mannoside treatment attenuates bladder and kidney infection. A) Schematic of mannoside treatment experiments. Male C3H/HeN mice were infected with
UTI89; after 5 d, mice were administered mannoside 29R (8 mg/kg/dose intraperitoneally (IP)) or vehicle (mock treatment) every 8 h for either 24 or 48 h. B)
Intratubular colonies of UPEC (teal) were observed 5 dpi in male C3H/HeN mice within desmoglein-2 positive (Dsg2+, red) collecting ducts (aquaporin-2 [AQP2]+,
green). DAPI, blue; scale bar, 10 μm. Mannoside treatment for 24 h (C) significantly reduced bacterial loads in the bladder (�p = 0.0255) and kidneys (�p = 0.0434)
(n = 8–10 mice per group over 2 independent experiments), while an even more significant effect was seen with 48 h treatment (D; bladder ���p = 0.0003, kidneys
��p = 0.0042; n = 8 mice per group over 2 independent experiments).
https://doi.org/10.1371/journal.ppat.1009314.g006
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pyelonephritis strain CFT073 expresses the PapGII variant [21]). These three alleles exhibit dif-
fering affinity for various glycolipid receptors that are differentially expressed in the kidneys of
humans and model animals–including mice, where further differences exist among back-
grounds [2,66]. Beyond our in vivo results, we found that P pili were also unnecessary for
UPEC binding to IMCD-3 cells (S6 Fig). Finally, while P pili are enriched in the genomes of
pyelonephritis-associated UPEC isolates for children with acute pyelonephritis, a significant
proportion of UPEC isolates from women with acute and recurrent UTI lack P pili, suggesting
a role for other adhesin(s) during ascending infection [21,67–70].
Recent works have employed new mouse models (including C3H/HeOuJ mice, male C3H/
HeN mice, and androgenized female mice) which now enable detailed study of the pathogene-
sis of kidney infection and abscess formation [29,37,51]. In our model of ascending UTI, type
1 pili were shown to be essential for maintenance of renal infection, through both genetic
mutation of the pilus and pharmacological inhibition with mannosides. Other work has hinted
at a role for type 1 pili and mannose targets in kidney infection [71–75]. For instance, an early
study in C3H/HeN female mice noted significant attenuation in both bladder and kidneys
upon deletion of fimH in E. coli strain 1177 that was rescued upon complementation [75]. Fur-
ther, signaling through C5a receptor 1 (C5aR1), which regulates inflammatory cell recruitment
in UPEC infection, may also enhance presentation of mannosylated glycoproteins by primary
renal tubular epithelial cells [72,73]. Meanwhile, experiments in which tubular infection was
initiated via microinjection of UPEC directly into rat nephrons posited a role for type 1 pili in
interbacterial interactions and biofilm formation [71]. While our work indicates that FimH
mediates renal epithelial binding (in agreement with prior staining of kidney sections using
purified adhesins [21,76]), the present work does not exclude a role for type 1 pili in interbac-
terial interactions and/or biofilm formation within the kidney. Inhibition of any of these inter-
actions by administration of mannosides might confer therapeutic benefit in pyelonephritis.
As the C3H mouse background used here features vesicoureteral reflux, it is conceivable that
ongoing bladder infection (enhanced by type 1 pili expression) may replenish the kidney niche.
The converse is also likely true, as suggested by the data in S1 Fig, where the lack of attenuation
of ΔfimH in the kidneys 24 hpi appears to obscure the bladder pathogenesis defect that would
be expected from prior work. Thus, the infected kidneys presumably can continually re-seed
the bladder niche. The absence of a kidney phenotype with ΔfimH 24 hpi may also indicate that
an alternative host-pathogen interaction is responsible for initial UPEC binding. The timing of
FimH action during UPEC kidney colonization is therefore an exciting avenue for future study.
Using a CRISPR-Cas9 screen, we identified desmoglein-2 as a receptor for UPEC during
ascending infection. DSG2 is a member of the cadherin family of Ca2+-binding proteins,
involved in intercellular junctions via the desmosome [77,78]. Its identified roles in mamma-
lian disease states are limited; of note, cardiomyocyte-specific conditional knockout of Dsg2 in
mice phenocopies human arrhythmogenic cardiomyopathy, which is correlated with loss-of-
function DSG2 mutations [79,80]. Interestingly, other members of the desmoglein family also
act as receptors for unrelated microbes [81]. Dsg2 has been specifically implicated as a receptor
for group B adenovirus serotypes 3, 7, 11, and 14 [82,83]; of note, serotype 11 is most com-
monly associated with hemorrhagic cystitis in renal and other transplant recipients [84].
Along the length of the nephron, DSG2 expression is highest within the collecting duct and
decreases as one ascends to more proximal segments of the tubule [59]. As a family, desmogle-
ins (and other cadherins) exhibit a unique form of mannosylation in which α-D-mannose (the
binding target of type 1 pili) is present as a novel O-linked glycosylation modification [58].
Prior studies have demonstrated FimH binding to N-linked glycans containing a terminal
mannose [7,10,85,86]. While N-linked glycans are present on each EC domain of DSG2 [58],
our data suggest that FimH interaction with native DSG2 is mediated through EC4 and/or
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EC5 (Fig 4). Of particular interest is the possibility that the cadherin-specific O-linked α-D-
mannose on EC4 may represent the preferred binding target. While FimH canonically binds
mannose, existing studies have not aimed to interrogate whether the spatial arrangement of
nearby amino acid residues may also influence binding affinity. Future work, including deter-
mination of the structural basis of DSG2-FimH binding, will further address this question.
One limitation of this study is that we were unable to obtain a complete Dsg2 knockout cell
line, indicating that complete absence of Dsg2 may confer a significant defect in in vitro
growth of IMCD-3 cells. It is becoming better appreciated that CRISPR-generated knockout
cell clones display phenotypic plasticity, and residual low-level protein expression often per-
sists [87]. Therefore, it is difficult to precisely quantify what proportion of UPEC binding is to
Dsg2 as opposed to other mannosylated cell-surface receptors. It is possible that Dsg2 knock-
down leads to compensatory production of other proteins; that Dsg2 knock-down reveals the
participation of more minor binding partners for type 1 pili; or that the amount of residual
Dsg2 in the knock-down clones provides sufficient receptors for UPEC to bind a modest pro-
portion of cells. The present data do not distinguish among these possibilities.
Our results indicate that Dsg2 may not be the sole receptor for UPEC within the kidney, but
rather the most important receptor among others on renal tubular epithelium. The apical sur-
faces of bladder epithelial facet cells are coated with a comparatively restricted set of proteins,
largely four uroplakins [88]. Among these, uroplakin Ia bearing N-linked oligomannose is
thought to be the primary receptor important for UPEC binding of intact bladder epithelium
[6–8,10,11,89]. In contrast, the renal tubular epithelium bears a wider variety of surface pro-
teins, a number of which might be mannosylated. Of note, CRISPR knock-down of the glycosyl-
transferase Dad1 on IMCD-3 cells also conferred a UPEC binding defect (Fig 3B), suggesting
that this enzyme may play a role in mannosylation of Dsg2 and/or other potential receptors for
UPEC type 1 pili. Additionally, multiple innate immune genes were statistically enriched in the
CRISPR screen (Fig 3B), hinting that innate response pathways may alter receptor expression
and thereby influence UPEC binding; this too represents an avenue for future study.
The present work highlights the importance of type 1 pili and the mannosylated epithelial
receptor desmoglein-2 in UPEC colonization of renal tubules. As the type 1 pilus adhesin
FimH is already targetable by small-molecule inhibitors and vaccines in patients with cystitis
[3,68,90], these therapeutics may prove useful in prevention or treatment of upper-tract UTI
as well. Finally, desmoglein-2 is expressed widely across many epithelia [55,57,91,92], suggest-
ing that it may serve as a FimH receptor in other UTI-relevant niches, perhaps as a secondary
receptor in the urinary bladder or in the gut.
Materials and methods
Ethics statement
All animal protocols complied with relevant ethical regulations and received prior approval
from the Institutional Animal Care and Use Committee at Washington University (approval
number 20180159).
Bacterial strains and growth
For mouse infections and for binding studies with IMCD-3 cells, bacteria were grown statically at
37˚C for 18 h in Luria-Bertani (LB) broth. For the CRISPR screen, type 1 pili were induced by
static growth at 37˚C for 18 h, then 1:100 subculture and static growth for an additional 18 h. Bac-
terial strains were all previously published, with mutations generated using the λ Red Recombi-
nase system [93] (see S2 Table). Bacteria were pelleted at 7,500 × g at 4˚C for 10 min, then
resuspended to an OD600 of 1.0 (~4 × 108 colony-forming units [CFU]/mL) in sterile phosphate-
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buffered saline (PBS) for mouse infections, or in DMEM F-12 (Invitrogen 1132–0033) supple-
mented with 10% fetal bovine serum (FBS; VWR 97068–085) for tissue culture experiments.
Mouse infections
Male C3H/HeN mice (Envigo) aged 8–9 weeks were infected as previously described [29]. Briefly,
mice were anesthetized with inhaled 3% isoflurane, and the lower abdomen was shaved and ster-
ilized with 2% chlorhexidine solution. A 3-mm midline abdominal incision was made through
the skin and peritoneum, exposing the bladder. The bladder was aseptically emptied before 50 μl
of inoculum (1–2 × 107 CFU in PBS) was injected into the bladder lumen via 30-gauge needle
over 10 s. The bladder was allowed to expand for an additional 10 s before the needle was
removed. The peritoneum and skin incisions were closed with simple, interrupted sutures. At the
time of surgery, mice were given sustained-release buprenorphine (1 mg/kg subcutaneously) for
analgesia. At the indicated time points, mice were euthanized by CO2 asphyxiation. Bladders and
kidney pairs were sterilely removed and homogenized in 1 mL or 0.8 mL PBS, respectively.
Homogenates were serially diluted and plated on LB agar for CFU enumeration.
Immunofluorescence microscopy
Infected bladders and kidneys were bisected and fixed in 10% neutral buffered formalin for 24
h. Fixed tissues were embedded in paraffin, sectioned, and stained. Unstained slides were depar-
affinized in xylenes, rehydrated in isopropanol, boiled in 10 mM sodium citrate, and blocked in
1% bovine serum albumin (BSA), 0.3% Triton-X 100 in PBS for 1–2 h at room temperature
(RT). Tissue culture cells were fixed in methanol at -20˚C for 10 min and then blocked in 3%
BSA for 1 h. Slides were incubated with primary antibodies for 4 h or overnight at RT and then
(after washing in PBS) with secondary antibodies for 1 h at RT. Slides were then mounted with
ProLong Gold antifade reagent (Invitrogen) and images acquired on an Olympus FV1200 con-
focal microscope. Primary antibodies utilized were: rabbit anti-type 1 pili (1:500 dilution), rab-
bit anti-E. coli (1:1000 dilution, E3500-06C; US Biological), goat anti-E. coli (1:100–1:500
dilution, B65109G; Meridian Life Science), mouse anti-AQP2 conjugated with AlexaFluor 488
or 647 (1:50–1:200 dilution, sc-515770; Santa Cruz Biotechnology), mouse anti-desmoglein 2
(1:100 dilution, 6D8, MCA2272T, BioRad), rabbit anti-desmoglein 2 (1:100, A303-758A, Bethyl
Labs). Secondary antibodies utilized were AlexaFluor 488-conjugated goat anti-rabbit IgG
(1:500 dilution, A11008; Life Technologies), AlexaFluor 647-conjugated chicken anti-rabbit IgG
(1:200, A-21443;ThermoFisher), AlexaFluor 594-conjugated donkey anti-goat IgG (1:200,
ab150132; abcam), Cy5-conjugated donkey anti-mouse IgG (1:250, 715-175-151; JacksonIm-
muno), AlexaFluor 488-conjugated goat anti-rabbit IgG (1:1000, 111-095-144; JacksonIm-
muno). Nuclear staining was with DAPI (1:10,000) or SYTO 61 (1:1000, Molecular Probes).
Tissue culture
Murine intramedullary collecting duct cells (IMCD-3; ATCC CRL-2123) were cultured in
DMEM F-12 supplemented with 10% FBS. Medium included 0.1 mg/mL penicillin-streptomy-
cin (Gibco 15140–122) until the day before an experiment, when medium was changed to the
above without antibiotics. Cells were maintained at 37˚C in a humidified atmosphere with 5%
CO2.
In vitro binding assays
The day before infection, IMCD-3 cells were seeded in 24-well plates. Medium was removed
and cells were washed with PBS supplemented with Mg2+ and Ca2+ (PBS-MgCa; Sigma-
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Aldrich D8662). After inoculation with UPEC at a multiplicity of infection (MOI) of 20, plates
were centrifuged at 400 × g for 3 min, then returned to the incubator. To enumerate bound
CFU, after 45 min, wells were washed 5 times with PBS-MgCa, then lysed with 0.1% Triton X-
100 (Sigma T9284). To enumerate internalized CFU, after 60 min, cells were washed with
PBS-MgCa, treated with medium containing 50 μg/mL gentamicin (Thermo Fisher
15750060), and incubated at 37˚C for 90 min, then lysed with 0.1% Triton X-100. Lysates were
serially diluted and plated to LB agar. Binding efficiencies were calculated in comparison to
input wells, in which cells were inoculated with UPEC, incubated for 45 min, then lysed by
addition of Triton X-100, and the well contents plated to LB agar for enumeration of input
CFU.
Flow cytometry
The day before infection, IMCD-3 cells were seeded in 6-well plates. Cells were infected with
UPEC (at MOI 20–150) for 45 min, then washed as described above; cells were liberated with
0.05% trypsin-0.02% EDTA (Gibco), pelleted, and fixed in 4% paraformaldehyde (Electron
Microscopy Sciences) for 30–60 min at RT. Cells were then blocked in 3% BSA for 1 h at RT.
Cells were stained with primary rabbit anti-E. coli antibody (1:500 dilution, E3500-06C; US
Biological) or isotype control (Rabbit serum; Sigma-Aldrich R9133) and secondary AlexaFluor
488-conjugated donkey anti-rabbit IgG (Invitrogen A21206) for 1 h each. Samples were stored
in 3% BSA until analyzed on a Becton Dickinson (BD) LSR II Fortessa flow cytometer. Gating
strategy is shown in S10 Fig.
Generation of virus and viral constructs
Viruses were generated by transfecting 293T cells with lentiviral cDNA (VSV-G, pMD2.G,
Addgene #12259; psPAX2, Addgene #12260; and construct of interest) using Opti-MEM
(Thermo Fisher 31985062) and TransIT LT1 transfection reagent (Mirus MIR2300). Virus was
harvested 48 h post transfection.
Library preparation and CRISPR screen
IMCD-3 cells were transduced with lentivirus containing Cas9 (pXPR_101, Addgene #52962)
by spinoculation (1 mL of Cas9 lentivirus onto 3 × 106 cells), then selected with 5 μg/mL blasti-
cidin (ThermoFisher A1113903). Cas9 activity was assayed by transducing cells with lentivirus
containing pXPR_011 (Addgene #59702), which expresses eGFP and a sgRNA targeting eGFP,
and selecting with 5 μg/mL puromycin (ThermoFisher A1113803). Loss of GFP expression in
cells expressing the eGFP guide was assessed by flow cytometry as described above. After Cas9
activity was confirmed, a Brie mouse sgRNA library (Brie pXPR_003, Batch 3, Lot #m-AA89-
20171107; generated by the Broad Institute) was transduced at MOI 0.5 into IMCD-3 Cas9
cells by spinoculation and selected with 5 μg/mL puromycin for 10 d until screening.
For screening, 5 × 106 IMCD-3 cells were seeded into eighty 15-cm dishes the day before
infection. Cells were infected with UTI89 at MOI 150 and incubated at 37˚C for 45–75 min,
then fixed and stained for flow cytometry as described above. Samples were placed at 4˚C over-
night on a tube roller; the following day, the 5% least FITC-positive cells were collected on a
Sony iCyt Synergy BSC sorter. Tubes containing these low-FITC sorted cells were centrifuged,
resuspended in 250 μl PBS, and stored at -20˚C. A total of 6 × 108 mock-treated cells were har-
vested, separated into aliquots of 8 × 107 cells, resuspended in 2 mL PBS, and stored at -20˚C
until genomic DNA preparation. DNA was extracted using QIAamp DNA Blood Maxi kit
(Qiagen 51192) for mock samples and QIAamp DNA FFPE Tissue kit (Qiagen 56404) for
experimental samples.
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Sequencing and bioinformatics
Illumina sequencing was performed as described previously [53]. Briefly, genomic DNA was
aliquoted into multiple wells of a 96-well plate (up to 10 μg of DNA in 50 μL total volume).
Samples were sequenced on an Illumina HiSeq 2000. Barcodes in the P7 primer were deconvo-
luted, and the sgRNA sequence was mapped to a reference file of sgRNAs in the Brie library.
To normalize for different numbers of reads per condition, read counts per sgRNA were nor-
malized to 107 total reads per sample; this normalized value was then log2 transformed. We
used the hypergeometric distribution method to rank sgRNAs and calculate gene p-values
using the probability mass function of a hypergeometric distribution (https://portals.
broadinstitute.org/gpp/public/analysis-tools/crispr-gene-scoring-help). We considered candi-
date genes those having an average log fold change>0.5 and a false discovery rate>2.5
[53,54]. For input of the hypergeometric distribution ranking, we subtracted the log2 normal-
ized read values of the uninfected unsorted IMCD-3 Brie library from the log2 normalized
read values of the 5% lowest UPEC-bound sorted cells. We used R Studio to visualize the
results of the hypergeometric distribution analysis.
Generation of Dsg2 knock-down clones (C4 and F11)
Dsg2 knock-down clones C4 and F11 were among hundreds generated by the Genome Engi-
neering and iPSC Center at Washington University School of Medicine. IMCD-3 cells were
nucleofected with Cas9 and a Dsg2-specific sgRNA (5’ GGAACTACGCATCAAAGTTCTGG
3’). Single-cell clones were isolated by FACS and expanded in 96-well plates. Cells were har-
vested, and genomic DNA was amplified and subjected to targeted deep sequencing of a
~400-bp amplicon flanking the gRNA target. Clones were screened for frameshifts by sequenc-
ing the target region with Illumina MiSeq at ~1500× coverage. We obtained no clones that
completely lacked Dsg2 expression. Frameshift mutations identified in knock-down clones C4
and F11 are detailed in S3 Table.
Quantitative PCR
RNA was isolated from tissue culture cells using the Qiagen RNeasy kit. qPCR was performed
using the Applied Biosystems TaqMan RNA-to-Ct 1-Step Kit (ThermoFisher 4392938) and
the probes listed in S4 Table (Integrated DNA Technologies).
Immunoblot
Samples were separated by SDS-PAGE and transferred to a polyvinylidene difluoride (PVDF)
membrane (Millipore) using overnight wet transfer (48mM Tris pH 9.2, 38mM glycine, 20%
methanol, 0.05% SDS). After blocking for 6–8 h with 5% milk in PBS-T, blots were probed
with rabbit anti-desmoglein-2 (1:250 dilution, A303-758A; Bethyl Labs) and mouse anti-β-
actin (1:100,000 dilution, 3700; Cell Signaling) in PBS-T with 5% milk overnight. Blots were
then secondarily probed with HRP-conjugated sheep anti-mouse IgG (1:1000 dilution,
NA931V; GE) and HRP-conjugated donkey anti-rabbit IgG (1:1000 dilution, NA934V; GE)
for 1 h. Gels were developed using Clarity and Clarity Max Western ECL substrates (1705060
and 1705062; BioRad). Western blot images were analyzed with ImageJ.
Protein production and biolayer interferometry (BLI)
Methods for purification of full-length FimH and the lectin domain (FimHLD; amino acids
1–160) have been described previously [10]. Briefly, untagged FimHLD was purified from E.
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coli periplasmic extracts using ion-exchange and size-exclusion chromatography, dialyzed into
sterile PBS, and stored at 4˚C until use.
Expression constructs for 6×His-tagged human DSG2 EC1-5 (amino acids A1-A553) or
DSG2 EC1-3 (amino acids A1-N332) (kind gifts of O. Harrison and L. Shapiro [58]) were
transfected (1 μg/mL of culture) into Expi293F cells (ThermoFisher) using 293fectin and Opti-
MEM. Six days post transfection, the supernatant containing the 6×His-tagged DSG2 ectodo-
mains was collected, dialyzed into 20mM Tris, 150mM NaCl pH 8 overnight at 4˚C, batch
purified by nickel-nitrilotriacetic acid (Ni-NTA) affinity chromatography, and then further
purified by HiLoad 16/600 Superdex 200 size-exclusion chromatography (GE Healthcare).
Protein was concentrated and was exchanged into a final buffer of sterile PBS, then stored at
4˚C until use in binding experiments. DSG2 EC1-5 was also expressed in Expi293F GnTI-
cells (which generate proteins lacking complex N-linked glycans but decorated only with high
mannose) and purified as described above.
All BLI experiments were performed in 10 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM
CaCl2, 3 mM EDTA, and 0.005% P20 surfactant with 1% BSA at 25˚C using an Octet-Red96
device (Pall ForteBio). DSG2 variants were biotinylated using EZ-Link NHS-PEG4-Biotin
(Thermo Fisher) per manufacturer’s instructions. Biotinylated DSG2 was loaded onto strepta-
vidin biosensors (ForteBio), then incubated with different concentrations of FimHLD or
FimHQ133K (10 μM to 156 nM) for 15 min followed by a 20 min dissociation. Real-time data
were analyzed using BIAevaluation 3.1 (GE Healthcare), and kinetic curves were fitted using a
global 1:1 binding algorithm with drifting baseline.
Mannoside treatment
Male C3H/HeN mice were infected as described above. Beginning 5 dpi, mice were given man-
noside FIM1033 (gift of Fimbrion Therapeutics), 8 mg/kg in sterile PBS with 4% DMSO, by
intraperitoneal injection every 8 h for 24 or 48 h. Mock-treated mice were injected with 4%
DMSO in sterile PBS. Mice were sacrificed 6 h post last treatment dose.
Statistical analysis
Statistical analysis was performed using Prism 8 (GraphPad Software). Differences were ana-
lyzed with the unpaired, two-tailed, nonparametric Mann-Whitney U test. P values<0.05
were deemed significant.
Supporting information
S1 Fig. Male C3H/HeN mice were infected with UTI89 (closed circles) or UTI89ΔfimH
(open diamonds), and organs were harvested 24 hpi. No significant differences in bacterial
loads between WT and ΔfimH were observed, indicating that ΔfimH reaches the kidney nor-
mally after inoculation of the bladder. Horizontal bars indicate geometric mean, and dotted
line indicates limit of detection. n = 9 mice per condition over 2 independent experiments.
(TIF)
S2 Fig. Male C3H/HeN mice were infected with CFT073 (closed circles) or CFT073ΔfimH
(open diamonds), and organs were harvested (A) 24 hpi or (B) 2 wpi. No significant dif-
ferences in bacterial loads were observed 24 hpi; ΔfimH was attenuated significantly 2 wpi
in both the bladder (�p = 0.0482) and kidneys (����p<0.0001). Horizontal bars indicate
geometric mean, and dotted line indicates limit of detection. A) n = 10 mice per condition
over 2 independent experiments; B) n = 13–14 mice per condition over 3 independent
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experiments.
(TIF)
S3 Fig. Male C3H/HeN mice were infected with UTI89 (closed circles) or isogenic, individ-
ual UTI89 CUP pili mutants (open diamonds), and organs were harvested 2 wpi. None of
these CUP pili mutants displayed defects in bladder or kidney colonization. Horizontal bars
indicate geometric mean, and dotted line indicates limit of detection. n = 6–18 mice per exper-
imental condition over 6 independent experiments.
(TIF)
S4 Fig. Male C3H/HeN mice were co-infected with antibiotic-tagged UTI89 (closed circles)
and each UTI89 CUP pilus mutant (open triangles). Bladders (A) and kidneys (B) were har-
vested 2 wpi and homogenates plated on selective media. Other than ΔfimH, none of the CUP
pilus mutants displayed defects in bladder or kidney colonization. Horizontal bars indicate
geometric mean, and dotted line indicates limit of detection. n = 3–9 mice per condition over
5 independent experiments.
(TIF)
S5 Fig. Functional variants of type 1 pili are ineffective in establishing kidney infection.
Male C3H/HeN mice were infected with UTI89 (closed circles) or with the indicated type 1
pili variants. Bladders and kidneys harvested 2 wpi yielded higher bacterial loads of wild-type
(WT) UTI89 compared to (A) UTI89 FimHA27V/V163A (open diamonds) (bladder
����p<0.0001, kidney ���p = 0.0001) or (B) UTI89 FimAA22R (open diamonds) (bladder
����p<0.0001, kidney ���p = 0.0038). Horizontal bars indicate geometric mean, and dotted
line indicates limit of detection. A) n = 13–19 mice per condition over 3 independent experi-
ments; B) n = 10–15 mice per condition over 2 independent experiments.
(TIF)
S6 Fig. Type 1 pili mediate UPEC binding to IMCD-3 cells. Cultured murine collecting duct
cells were infected with the indicated UPEC strains, and cells were stained with anti-E. coli
antibody and analyzed by flow cytometry; median fluorescence intensities are shown. Muta-
tion of fimH in UTI89 abrogated binding, while deletion of the P pilus usher (papC) had no
effect. Chromosomal re-integration of wild-type fimH, but not fimHQ133K, restored binding in
the UTI89 fimH mutant. Deletion of fimH in CFT073 similarly abrogated binding by this uro-
sepsis strain. n = 9–10 wells per condition (aggregate of three triplicate experiments).
����p<0.0001.
(TIF)
S7 Fig. Methyl α-D-mannopyranoside and mannoside FIM1033 inhibit UPEC binding to
collecting duct epithelial cells. A) FITC signal (anti-E. coli) on IMCD-3 cells infected with
wild-type UTI89 (navy blue) compared to infection with UTI89 ΔfimH (orange) or with wild-
type UTI89 in media containing 2% methyl α-D-mannopyranoside (teal). B) Binding of
IMCD-3 cells by UTI89 (closed circles) with or without addition of methyl α-D-mannopyrano-
side, or with ΔfimH (open diamonds), was quantified by flow cytometry after gating on single
cells. Significance is shown in comparison to WT UTI89 without methyl α-D-mannopyrano-
side (��p<0.01, ���p<0.001). n = 6–9 samples per condition over 3 independent experiments.
C) FITC signal (anti-E. coli) on IMCD-3 cells infected with wild-type UTI89 (navy blue) com-
pared to infection with UTI89 ΔfimH (orange) or with wild-type UTI89 in media containing
FIM1033 (0.1μM, light pink; 1μM, dark pink; 10μM, maroon). D) Binding of IMCD-3 cells by
WT UTI89 (closed circles) with or without addition of FIM1033, or by ΔfimH (open dia-
monds), was quantified by flow cytometry after gating on single cells. Horizontal bars indicate
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geometric mean, and significance is shown in comparison to WT UTI89 without FIM1033
(����p<0.0001). n = 9 samples per condition over 3 independent experiments.
(TIF)
S8 Fig. Purification of 6×His-tagged DSG2 EC1-5 from Expi293F cells. A) Coomassie blue-
stained gel of FimHLD and FimHQ133K. B) Coomassie blue-stained gel after metal-affinity puri-
fication of DSG2 EC1-5 and EC1-3 from cell supernatant. DSG2 EC1-5 was expressed in both
WT Expi293F cells as well as in Expi293F GnTI- cells (lacking complex glycans). In right
panel, due to its immunoglobulin folds, addition of the reducing agent DTT alters the apparent
molecular weight (MW) of DSG2 EC1-5, from ~70 kDa to ~75 kDa.
(TIF)
S9 Fig. Biolayer interferometry (BLI) tracings for binding of FimHLD to immobilized
DSG2 EC1-5 expressed from WT Expi293F cells (left panel) or Expi293F GnTI- cells (right
panel). A 1:1 binding model (red lines) was used to fit experimental curves (black lines). Rep-
resentative curves shown from 5 independent BLI runs per condition; affinity values represent
the mean ± SD of two independent experiments.
(TIF)
S10 Fig. Gating strategy for flow cytometry experiments. Samples were gated on single cells.
Representative samples of IMCD-3 cells treated with medium alone (red) and WT UTI89
(blue) shown.
(TIF)
S1 Table. CRISPR screen analyzed ranks and statistics.
(XLSX)
S2 Table. Strains used in this study.
(DOCX)
S3 Table. Frameshift mutations within Dsg2 in IMCD-3 clones C4 and F11 (two allelic var-
iants present in each clone are shown).
(DOCX)
S4 Table. Probes and primers for qPCR.
(DOCX)
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